Cargando…

Long non-coding RNA PCDRlnc1 confers docetaxel resistance in prostate cancer by promoting autophagy

Docetaxel resistance seriously affects its clinical application in prostate cancer (PCa). Long noncoding RNAs (lncRNAs) influence the chemosensitivity of various cancers. However, the potential involvement of lncRNAs in docetaxel sensitivity remains largely unknown in PCa. In the present study, we u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Jianjun, Chen, Xiumei, wang, Weiwan, Guan, Zhenghui, Hou, Jianquan, Lin, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066218/ https://www.ncbi.nlm.nih.gov/pubmed/35517427 http://dx.doi.org/10.7150/jca.65329

Ejemplares similares

FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A
por: Yu, Hongbo, et al.
Publicado: (2020)

Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells
por: Cristofani, Riccardo, et al.
Publicado: (2018)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Combination of Kaempferol and Docetaxel Induces Autophagy in Prostate Cancer Cells In Vitro and In Vivo
por: Zhou, Qian, et al.
Publicado: (2023)

Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine
por: Lamprou, Ioannis, et al.
Publicado: (2021)

HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma
por: Pan, Banzhou, et al.
Publicado: (2014)

SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer
por: Zielske, Steven P., et al.
Publicado: (2023)

PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy
por: Zeng, Jin, et al.
Publicado: (2018)

Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer
por: Babasaki, Takashi, et al.
Publicado: (2021)

Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy
por: Wang, Meng, et al.
Publicado: (2018)

Undifferentiated prostate cancer treated with docetaxel
por: Kobayashi, Masaki, et al.
Publicado: (2020)

The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review
por: Chen, Long, et al.
Publicado: (2014)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism
por: Chen, Liang, et al.
Publicado: (2022)

Metformin exerts anti-AR-negative prostate cancer activity via AMPK/autophagy signaling pathway
por: Chen, Chunyang, et al.
Publicado: (2021)

Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells
por: Guo, Jianquan, et al.
Publicado: (2015)

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
por: James, Nicholas D, et al.
Publicado: (2022)

Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017)

Long non-coding RNAs involved in autophagy regulation
por: Yang, Lixian, et al.
Publicado: (2017)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017)

Long Non-Coding RNA Reprogramming (ROR) Promotes Cell Proliferation in Colorectal Cancer via Affecting P53
por: Li, Hong, et al.
Publicado: (2017)

Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations
por: Chi, Chenfei, et al.
Publicado: (2022)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy
por: Jia, Jing, et al.
Publicado: (2019)

Long Non-coding RNA LINC01094 Promotes the Development of Clear Cell Renal Cell Carcinoma by Upregulating SLC2A3 via MicroRNA-184
por: Xu, Haifei, et al.
Publicado: (2020)

Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells
por: Sanchez-Hernandez, Evelyn S., et al.
Publicado: (2023)

Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Leads to Greater Anti-tumor Activity of Docetaxel in Advanced Prostate Cancer
por: Lin, Jianzhong, et al.
Publicado: (2013)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
por: Huang, Houbao, et al.
Publicado: (2020)

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
por: Ntekim, A.I., et al.
Publicado: (2010)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
por: O'Neill, Amanda J, et al.
Publicado: (2011)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
por: Kopczyńska, Ewa
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a1o051ica9kqc17he7co90nln3